Truist Financial Corp Sells 594 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Truist Financial Corp cut its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 14.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,461 shares of the company’s stock after selling 594 shares during the quarter. Truist Financial Corp’s holdings in TransMedics Group were worth $216,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Venturi Wealth Management LLC boosted its stake in shares of TransMedics Group by 33.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock valued at $136,000 after purchasing an additional 219 shares during the last quarter. National Bank of Canada FI grew its stake in TransMedics Group by 174.7% during the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after acquiring an additional 262 shares in the last quarter. Quarry LP grew its stake in TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after buying an additional 312 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after acquiring an additional 316 shares during the last quarter. Finally, Park Avenue Securities LLC raised its holdings in TransMedics Group by 3.8% during the 4th quarter. Park Avenue Securities LLC now owns 8,797 shares of the company’s stock valued at $548,000 after buying an additional 322 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Stock Down 3.2 %

NASDAQ TMDX opened at $65.29 on Friday. The business has a fifty day moving average price of $68.18 and a 200 day moving average price of $98.89. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The company has a market cap of $2.20 billion, a P/E ratio of 69.46 and a beta of 2.12.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. TD Cowen reduced their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Robert W. Baird cut their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Oppenheimer reiterated an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a research report on Tuesday, December 3rd. JPMorgan Chase & Co. restated a “neutral” rating and issued a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Finally, Canaccord Genuity Group dropped their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.